FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 693 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR What the Reignited Cancer Moonshot Initiative Means for People With Cancer March 29, 2022 Reduction Not Only in Recurrences, but Also in Mortality, Observed for... December 20, 2022 Cancerul în comunitatea mea: progresul îngrijirilor pentru cancer în România August 4, 2020 Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... December 5, 2021 Load more HOT NEWS Coping With Cancer Recurrence: My Perspective As Both a Patient and... For Some Kids with Brain Cancer, Targeted Therapy is Better than... Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among... Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with...
